Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
per week
for 24 weeks
// //

Atrion Corp NASDAQ: ATRI-Q

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

More stories below advertisement

Atrion Reports First Quarter Results

GlobeNewswire - Mon May 10, 3:30PM CDT

Atrion Corporation (Nasdaq - ATRI) today announced that revenues for the quarter ended March 31, 2021 were $39.2 million compared with $43.6 million for the first quarter of 2020. Net income in the current-year quarter totaled $7.7 million compared to $8.9 million in last year's first quarter, with diluted earnings per share for the first quarter of 2021 at $4.22 compared to $4.79 for the first quarter of 2020.

Commenting on results for the first quarter of 2021 and the outlook for the remainder of 2021, Mr. Battat stated, "I am very pleased to report strong growth in quarterly sequential sales, with revenues for the first quarter of 2021 increasing by $7.0 million compared to the preceding quarter. After three successive quarters of sales declines in 2020 during the pandemic we have turned the corner. Our customers are placing increased orders, reflecting the pent-up demand for postponed inpatient and outpatient procedures. Given the easing of quarantine restrictions and the increased availability of vaccines, we expect a continued ramp-up in the number of elective surgeries in each of the remaining quarters of this year, albeit at a modest pace in the second quarter as many people will choose to travel in the late spring and early summer months. As a result, we are confident in our outlook for 2021 and expect revenues in the second half of the year and beyond to continue on a growth path."

Addressing comparisons with the first quarter of 2020, Mr. Battat added, "While the effect of COVID-19 on revenues is diminishing, we are continuing to employ enhanced safety measures in our facilities to protect our workforce, even though this impacts our efficiency and skews pre-pandemic comparisons. Moreover, we have addressed the added financial burdens facing our employees due to the pandemic for expenses such as child care and remote schooling by increasing pay for our manufacturing employees. These cost increases, which we incurred in the just-completed first quarter and are continuing, are the primary reason why gross margins declined from 46% of sales in the first quarter of 2020 to 42% in the just completed quarter of 2021. Nevertheless, operating income in the first quarter of 2021 was a very strong 23% of sales."

Mr. Battat concluded, "Cash and short and long term investments increased slightly to $88.5 million, and we remain debt free."

Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is

Statements in this press release that are forward looking are based upon current expectations and actual results or future events may differ materially. Such statements include, but are not limited to, Atrion's expectations regarding a continued increase in elective surgeries in each of the remaining quarters of 2021 and revenues in the second half of 2021 to continue on a growth path. Words such as "expects," "believes," "anticipates," "forecasts," "intends," "should", "plans," "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements contained herein involve numerous risks and uncertainties, and there are a number of factors that could cause actual results or future events to differ materially, including, but not limited to, the following: the risk that the COVID-19 pandemic continues to lead to material delays and cancellations of, or reduced demand for, procedures in which our products are utilized; curtailed or delayed capital spending by hospitals and other healthcare providers; disruption to our supply chain; closures of our facilities; delays in training; delays in gathering clinical evidence; diversion of management and other resources to respond to the COVID-19 outbreak; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 virus continues to disrupt local economies and to cause economies in our key markets to enter prolonged recessions; changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; the impact of competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; implementation of new manufacturing processes or implementation of new information systems; our ability to protect our intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product liability claims and product recalls; the ability to attract and retain qualified personnel; and the loss of, or any material reduction in sales to, any significant customers. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic review which may cause us to alter our marketing, capital expenditures or other budgets, which in turn may affect our results of operations and financial condition. The foregoing list of factors is not exclusive, and other factors are set forth in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date hereof, and we do not undertake any obligation, and disclaim any duty, to supplement, update or revise such statements, whether as a result of subsequent events, changed expectations or otherwise, except as required by applicable law.

Contact: Jeffery Strickland
         Vice President and Chief Financial Officer
         (972) 390-9800



(In thousands, except per share data)


Three Months Ended
                                            March 31,
                                               2021          2020
Revenues                                    $  39,169     $  43,594
Cost of goods sold                             22,830        23,726
Gross profit                                   16,339        19,868
Operating expenses                             7,408         8,154
Operating income                               8,931         11,714
Interest and dividend income                   217           462
Other investment income (loss)                 62            (997   )
Other income                                   66            --
Income before income taxes                     9,276         11,179
Income tax provision                           (1,550 )      (2,281 )
Net income                                     7,726         8,898
Income per basic share                      $  4.23       $  4.80
Weighted average basic shares outstanding      1,826         1,853
Income per diluted share                    $  4.22       $  4.79
Weighted average diluted shares outstanding    1,832         1,859



(In thousands)

Mar. 31,       Dec. 31,
ASSETS                                2021           2020
Current assets:
Cash and cash equivalents             $     29,427   $    22,450
Short-term investments                      18,393        19,258
Total cash and short-term investments       47,820        41,708
Accounts receivable                         20,235        16,445
Inventories                                 49,519        50,298
Prepaid expenses and other                  2,385         3,868
Total current assets                        119,959       112,319
Long-term investments                       40,672        46,207
Property, plant and equipment, net          94,891        94,935
Other assets                                13,321        13,429
                                      $     268,843  $    266,890
Current liabilities                         10,777        13,636
Line of credit                              --            --
Other non-current liabilities               13,315        12,812
Stockholders' equity                        244,751       240,442
                                      $     268,843  $    266,890

comtex tracking


More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies